Pfizer Inc. faced a significant drop in its stock price on December 16, 2025, following the release of its financial guidance for 2026, which disappointed investors and analysts alike, as analysts warn in the report.
Pfizer's Earnings Projection Falls Short
The pharmaceutical company projected adjusted earnings per share between 280 and 300, falling short of the analyst consensus estimate of 305. This shortfall is largely attributed to a continued decline in demand for its COVID-19 vaccine and antiviral treatments, which have been pivotal to its revenue streams in recent years.
Market Reaction to Pfizer's Stock Price
As trading progressed into the midmorning, Pfizer's stock price plummeted nearly 4%, signaling growing investor concerns regarding the company's future earnings potential. The market's reaction underscores the challenges Pfizer faces as it navigates a post-pandemic landscape where demand for its COVID-related products is waning.
On December 15, 2025, ServiceNow's stock fell by 4% in premarket trading due to news of a potential acquisition of cybersecurity firm Armis, raising investor concerns. For more details, see the full article here.
